Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

被引：7
|
作者：
Han, H. S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Dieras, V. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Robson, M. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Palacova, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Marcom, P. K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Jager, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Bondarenko, I. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Citrin, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Campone, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Telli, M. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Domchek, S. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Friedlander, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Man, B. Kauf [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Ratajczak, C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Coates, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Bonnet, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Qin, Q. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Qian, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Giranda, V. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Shepherd, S. P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Isakoff, S. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Puhalla, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Inst Curie, Paris, France
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Masarykuv Onkol Ustav, Brno, Czech Republic
[5] Duke Univ, Durham, NC USA
[6] Erasmus MC Canc Inst, Rotterdam, Netherlands
[7] Dnepropetrovsk City Hosp, Dnepropetrovsk, Ukraine
[8] Midwestern Reg Med Ctr, Zion, IL USA
[9] Inst Cancerol Ouest, St Herblain, France
[10] Stanford Univ, Sch Med, Stanford, CA USA
[11] Univ Penn, Philadelphia, PA 19104 USA
[12] Prince Wales Hosp, Sydney, NSW, Australia
[13] Sheba Med Ctr, Tel Hashomer, Israel
[14] AbbVie Inc, Chicago, IL USA
[15] Massachusetts Gen Hosp, Boston, MA 02114 USA
[16] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-S2-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S2-05
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V plus TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer
    Dieras, V.
    Han, H. S.
    Robson, M. E.
    Palacova, M.
    Marcom, P. K.
    Jager, A.
    Bondarenko, I.
    Citrin, D.
    Campone, M.
    Telli, M. L.
    Domchek, S. M.
    Friedlander, M.
    Kaufman, B.
    Ratajczak, C.
    Coates, A.
    Bonnet, P.
    Qin, Q.
    Qian, J.
    Giranda, V. L.
    Shepherd, S. P.
    Puhalla, S.
    Isakoff, S. J.
    CANCER RESEARCH, 2017, 77
  • [2] A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer
    Isakoff, S. J.
    Pulhalla, S.
    Shepherd, S. P.
    Falotico, N.
    Kaufman, B.
    Friedlander, M.
    Robson, M.
    Domchek, S.
    Garber, J.
    McKeegan, E.
    Chyla, B.
    Qian, J.
    Giranda, V. L.
    CANCER RESEARCH, 2012, 72
  • [3] Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).
    Huggins-Puhalla, Shannon Leigh
    Han, Hyo S.
    Dieras, Veronique
    Friedlander, Michael
    Somlo, George
    Arun, Banu
    Wildiers, Hans
    Kaufman, Bella
    Ayoub, Jean-Pierre M.
    Shah, Melissa
    Burmedi, David
    Qin, Qin
    Qian, Jane
    Giranda, Vincent L.
    Shepherd, Stacie Peacock
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [4] Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).
    Puhalla, Shannon
    Han, Hyo S.
    Dieras, Veronique
    Friedlander, Michael
    Somlo, George
    Arun, Banu
    Wildiers, Hans
    Kaufman, Bella
    Ayoub, Jean-Pierre M.
    Shan, Melissa
    Burmedi, David
    Qin, Qin
    Qian, Jane
    Giranda, Vincent L.
    Shepherd, Stacie Peacock
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
    Han, H. S.
    Dieras, V.
    Robson, M.
    Palacova, M.
    Marcom, P. K.
    Jager, A.
    Bondarenko, I.
    Citrin, D.
    Campone, M.
    Telli, M. L.
    Domchek, S. M.
    Friedlander, M.
    Kaufman, B.
    Garber, J. E.
    Shparyk, Y.
    Chmielowska, E.
    Jakobsen, E. H.
    Kaklamani, V.
    Gradishar, W.
    Ratajczak, C. K.
    Nickner, C.
    Qin, Q.
    Qian, J.
    Shepherd, S. P.
    Isakoff, S. J.
    Puhalla, S.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 154 - 161
  • [6] A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
    Isakoff, Steven J.
    Puhalla, Shannon
    Domchek, Susan M.
    Friedlander, Michael
    Kaufman, Bella
    Robson, Mark
    Telli, Melinda L.
    Dieras, Veronique
    Han, Hyo Sook
    Garber, Judy E.
    Johnson, Eric F.
    Maag, David
    Qin, Qin
    Giranda, Vincent L.
    Shepherd, Stacie P.
    FUTURE ONCOLOGY, 2017, 13 (04) : 307 - 320
  • [7] Safety and Efficacy of Veliparib Plus Carboplatin/Paclitaxel in Patients With HER2-Negative Metastatic or Locally Advanced Breast Cancer: A Subgroup Analysis of Germline BRCA1 or BRCA2 Mutations From the Phase 3 BROCADE 3 Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 16 - 17
  • [8] Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2-(BRCA)-associated metastatic breast cancer (MBC).
    Somlo, George
    Frankel, Paul Henry
    Luu, Thehang H.
    Ma, Cynthia X.
    Arun, Banu
    Garcia, Agustin A.
    Cigler, Tessa
    Cream, Leah
    Harvey, Harold A.
    Sparano, Joseph A.
    Nanda, Rita
    Chew, Helen K.
    Moynihan, Timothy Jerome
    Vahdat, Linda T.
    Goetz, Matthew P.
    Hurria, Arti
    Mortimer, Joanne E.
    Gandara, David R.
    Chen, Alice P.
    Weitzel, Jeffrey N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline BRCA1 or BRCA2 mutations from the phase 3 BROCADE3 trial
    Wildiers, Hans
    Ayoub, Jean-Pierre
    Friedlander, Michael
    Kaufman, Bella
    Arun, Banu K.
    Han, Hyo S.
    Puhalla, Shannon L.
    Maag, David
    Feng, Dai
    Ratajczak, Christine K.
    Bach, Bruce A.
    Dieras, Veronique
    CANCER RESEARCH, 2021, 81 (04)
  • [10] A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC).
    Viswanathan, S.
    Wesolowski, R.
    Layman, R. M.
    Alejandra, G.
    Miller, B.
    Chalmers, J. J.
    Bejastani, S.
    Zhao, W.
    Pierluigu, G.
    Cotrill, J.
    Phelps, M. A.
    Schaaf, L. J.
    Geyer, S. M.
    Hall, N.
    Knopp, M. V.
    Shapiro, C. L.
    Villalona-Calero, M. A.
    Chen, A.
    Grever, M. R.
    Ramaswamy, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345